Dirk Block
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dirk Block.
Journal of Internal Medicine | 2013
Serge Masson; Roberto Latini; G. F. Mureddu; N. Agabiti; M. Miceli; G. Cesaroni; F. Forastiere; U.H. Wienhues-Thelen; Dirk Block; Christian Zaugg; T. Vago; A. Boccanelli
To investigate the association between circulating cardiac biomarkers and minor abnormalities in cardiac phenotype [left ventricular (LV) mass and midwall fractional shortening (MFS)] in elderly individuals in a general population sample.
The Cardiology | 2015
Thor Ueland; P. Aukrust; St le H. Nymo; John Kjekshus; John J.V. McMurray; John Wikstrand; Ursula-Henrike Wienhues-Thelen; Dirk Block; Christian Zaugg; Lars Gullestad
Objectives: Increased circulating endostatin levels have been demonstrated in progressive cardiovascular (CV) and renal disorders. We investigated the predictive value of endostatin in patients with chronic heart failure (HF) and the association between endostatin and renal function. Methods: The interaction between serum endostatin, estimated glomerular filtration rate (eGFR) and predefined endpoints, including the primary endpoint (CV death, nonfatal myocardial infarction, nonfatal stroke; n = 397), all-cause mortality (n = 410), CV death (n = 335) or the coronary endpoint (n = 317), was evaluated in 1,390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, who were randomly assigned to 10 mg rosuvastatin or placebo. Results: In the population as a whole, endostatin added no predictive information after full multivariable adjustment including eGFR and N-terminal pro-brain natriuretic peptide. Serum endostatin was strongly correlated with eGFR (r = 0.59, p < 0.001). After full multivariable adjustment, an association between high serum endostatin and increased risk of all-cause mortality and decreased risk of the primary and coronary endpoints was seen in HF patients with impaired and preserved renal function, respectively. Conclusions: Endostatin added no predictive information regarding the adverse outcome in patients with chronic systolic HF of ischemic etiology. An increased risk of all-cause mortality was seen in patients with decreased renal function. i 2014 S. Karger AG, Basel
Archive | 2005
Dirk Block; Ruediger Haenel; Joerg Kleiber; Manuela Poignee-Heger; Thomas Walter; Ralf Zielenski
Archive | 2011
Dirk Block; Christine Böhm; Georg Hess; Andrea Horsch; Hendrik Hüdig; Sabine Vogel-Ziebolz; Ursula-Henrike Wienhues-Thelen; Dietmar Zdunek
Journal of Cardiac Failure | 2015
Thor Ueland; Pål Aukrust; Ståle H. Nymo; John Kjekshus; John J.V. McMurray; John Wikstrand; Dirk Block; Christian Zaugg; Lars Gullestad
Scandinavian Journal of Clinical & Laboratory Investigation | 2001
Hans-Peter Lehmann; Dirk Block; Christine Markert-Hahn; J. Werner Zolg
Archive | 2010
Ursula-Henrike Wienhues-Thelen; Dirk Block; Hendrik Huedig
Archive | 2007
Dirk Block; Georg Hess; Hendrik Huedig; Der Eltz Herbert Von; Ursula-Henrike Wienhues-Thelen; Andrew Emili; Vincent Fong; Anthony Gramolini; Ruth Isserlin; Thomas Kislinger; Peter Liu; David Maclennan
Archive | 2014
Dirk Block; Serge Masson; Ursula-Henrike Wienhues-Thelen; Christian Zaugg; Roberto Latini
Archive | 2014
Christian Zaugg; Dirk Block; Ursula-Henrike Wienhues-Thelen; Hans-Peter Brunner; Friedemann Krause; Fabian Model; Vincent Rolny